Enfortumab vedotin (Padcev)

At a glance

Enfortumab vedotin (Padcev) is an antibody–drug conjugate, often shortened to ADC. It combines an antibody that recognises a target on cells with a cell-killing medicine. It is given by a trained team through a drip into a vein. Although it is targeted treatment, it can affect healthy tissues and needs careful monitoring.

Pay particular attention to new skin changes, increased thirst, nerve symptoms and breathing problems. Skin reactions can become serious early in treatment, and high blood sugar can occur even in someone without known diabetes. Enfortumab is sometimes given with pembrolizumab, which adds its own immune-related risks.

Follow your own treatment calendar and the advice from your care team. Keep your medicine names and treatment dates handy to share with other clinicians.

How it works

The antibody recognises Nectin-4, a protein on the surface of certain cells. It carries monomethyl auristatin E, or MMAE, a medicine that interferes with structures needed for cell division. After entering a target cell, the attached medicine can damage or kill it. Enfortumab is the ADC; pembrolizumab, when prescribed with it, is a separate immune checkpoint inhibitor.

The antibody, its chemical link and the attached medicine form one product. They are not separate medicines that you can take in different amounts yourself. Targeting helps deliver treatment to particular cells, but it does not mean that only cancer cells are affected. Side effects can come from the attached medicine, the antibody, your existing illness or accompanying treatment.

An ADC is different from an immune checkpoint inhibitor, even when both are given in the same treatment plan. A reaction or noticeable side effect is not proof that an ADC is working. Equally, having few side effects does not mean that treatment has failed.

Is this treatment suitable for me?

Enfortumab vedotin is used for urothelial cancer, including selected locally advanced or metastatic disease, and with pembrolizumab before and after bladder-removal surgery in selected muscle-invasive bladder cancers. Eligibility depends on the treatment setting, previous treatment and fitness for other therapies. Your oncologist will advise whether it is suitable for you, taking account of your cancer type, relevant test results, previous treatment, overall health and the applicable prescribing information and regulatory guidance in your country.

Your team considers previous treatment, liver function, existing neuropathy, skin disease, eye symptoms and blood-sugar control. Nectin-4 is the drug’s target, but a separate Nectin-4 test is not routinely required for every prescription. Diabetes and previous severe skin reactions need explicit discussion. The suitability of accompanying pembrolizumab is assessed separately. Moderate or severe liver impairment needs particular specialist review: US information advises avoiding enfortumab, while European information has insufficient evidence for a specific dose recommendation.

The discussion should cover the aim of treatment, the alternatives, likely appointments and how benefit will be assessed. A target found in a sample is one part of this decision; it does not guarantee a response. Tell the team what matters to you, including independence, work, caring responsibilities and the practical support available at home.

Before treatment

Bring a complete list of prescribed and non-prescribed medicines, vitamins, herbal products and allergies. Mention previous difficult reactions to infusions, infections, diabetes, liver or kidney problems and any pregnancy or breastfeeding. Explain symptoms you already have so a later change is easier to recognise.

Blood tests include glucose, blood counts and organ function. Pregnancy testing is needed if you could become pregnant; European information specifies testing within seven days before treatment. Describe your usual skin condition, any foot or hand numbness, and any cough or breathlessness. If you have diabetes, agree how often glucose will be checked at home and whom to contact for high readings. Eye dryness or existing vision problems should also be recorded.

A nurse or pharmacist should explain the supportive medicines and which ones start before the treatment day. Ask your team to help you plan when to take each medicine. Make sure you know how to reach your hospital's urgent oncology service outside clinic hours. You may find it helpful to save the instructions on your phone or keep a copy at home. A family member or friend can help you remember them.

Discuss fertility preservation before treatment if future parenthood matters to you. Tell the team about dental problems and planned procedures. A procedure may need to be timed around blood counts and infection risk. Do not postpone reporting an active dental infection while waiting for the next routine appointment.

How treatment is given

A usual starting dose is 1.25 mg/kg, capped at 125 mg per dose, infused over about 30 minutes. When used alone, it is commonly given on days 1, 8 and 15 of a 28-day cycle. With pembrolizumab, enfortumab is usually given on days 1 and 8 of a 21-day cycle and is administered first when both medicines are due that day. Some plans around surgery have a fixed number of cycles; other plans continue while benefit and tolerance support treatment.

Dose reductions or interruptions may be required for skin, nerve, blood-sugar or other toxicities. This is not a self-injected medicine. Pembrolizumab may have a different appointment interval and route depending on its formulation, so keep both names on your calendar.

Treatment is delivered through a cannula in a vein, a central line or an implanted port, depending on the plan and available access. Staff check the medicine, your identity, blood results and recent symptoms before starting. The appointment includes preparation and monitoring, so it will usually take longer than the infusion itself.

Tell the nurse immediately if you notice burning, pain, swelling, redness, leakage or tightness around the infusion site. These can mean medicine is leaking outside the vein. Do not wait for the drip to finish. At home, report a site that becomes more painful, blistered or discoloured, even if it looked normal when you left.

Also report flushing, itching, shivering, chest or back discomfort, wheezing, dizziness or swelling during treatment. Staff can stop or slow the infusion and assess you. Do not adjust the pump or line yourself. If a line remains in place, follow its cleaning and dressing instructions and report fever, tenderness or drainage around it.

If an appointment is missed, contact the treatment unit to arrange the next dose. Do not simply wait for the following cycle or seek an extra dose elsewhere. The correct restart date depends on why the dose was missed, the treatment schedule and recovery from side effects.

Monitoring your treatment

Blood tests usually check infection-fighting cells, red cells, platelets, kidney function and liver function. Some abnormalities cause no early symptoms. A reassuring blood test does not make a new symptom safe to ignore, and feeling well is not a reason to miss monitoring.

Glucose is checked because severe hyperglycaemia and diabetic ketoacidosis can occur. The clinical team withholds enfortumab for blood glucose above 250 mg/dL under the product instructions; your personal action threshold may be lower. Do not wait for that number if you have symptoms. Skin, nerve function and breathing are reviewed repeatedly. Kidney and liver results and blood counts help guide each dose.

Your team compares examinations, symptoms and relevant scans or disease tests over time. Ask when the first response assessment is planned and what the result could change. A treatment break or lower dose may protect you from accumulating harm while allowing further treatment. It is not automatically evidence that the cancer has worsened. Never try to compensate for a reduced dose with supplements or closer appointments.

Common side effects

Side effects vary between people and between treatment combinations. You may experience several, a few or none of those described. Tell the team about symptoms that interfere with eating, sleeping, walking or usual tasks; a problem does not need to be severe before support is worthwhile.

Rash, itching and dry skin

Use a gentle moisturiser and avoid irritating products. Photograph a new rash if useful, but report it to the team rather than relying on a photograph at the next visit. Tenderness, skin pain, blisters, peeling, fever or sores in the mouth or eyes can indicate a serious reaction. These require urgent assessment even when the rash started as a small patch.

Nerve symptoms and dry eyes

Tingling, burning, numbness or weakness in hands and feet may accumulate. Report changes in walking, grip or balance early. Moderate neuropathy requires a pause and severe neuropathy requires permanent discontinuation under the treating team’s direction. Lubricating drops may be recommended for dry eyes. New blurred vision, pain or persistent eye irritation needs assessment; do not use steroid eye drops without an appropriate eye examination and prescription.

Taste and hair changes

Food may taste different and hair may thin or fall out. Try foods you can tolerate and ask for dietetic support if intake drops. Scalp and hair changes vary, especially when previous or accompanying treatments contribute.

Tiredness and reduced stamina

Plan important tasks for the part of the day when you have most energy and accept practical help. Short periods of gentle activity can be useful, with rest between them. Sudden marked weakness, breathlessness, dizziness or a racing heart needs assessment for causes such as anaemia, infection or dehydration. Do not assume every new limitation is ordinary treatment fatigue.

Nausea, appetite and bowel changes

Take prescribed anti-sickness medicines on the agreed schedule. Small regular meals, cool foods and frequent sips can be easier to manage. Tell the team if you cannot keep medicines or fluids down, are passing little urine or are losing weight. A dietitian can help when eating becomes difficult.

Record loose stools and whether there is pain, blood or fever. Severe diarrhoea, repeated vomiting or a swollen painful abdomen needs prompt advice. Constipation can be worsened by anti-sickness drugs and pain relief; use the bowel plan your team recommends. Do not repeatedly add laxatives or anti-diarrhoeal medicines without checking when there is significant pain or other new illness.

Low blood counts

A low white cell count can make infection progress quickly. Follow the urgent-help instructions below. Low red cells can cause tiredness, pallor or breathlessness; sometimes transfusions are needed. Low platelets can cause easy bruising, nosebleeds, bleeding gums or tiny red-purple spots. Report new bleeding and avoid starting aspirin or anti-inflammatory painkillers without checking. Do not stop a prescribed blood thinner yourself; the team must balance bleeding and clotting risks.

Mouth comfort and skin care

Use a soft toothbrush and the mouth-care products advised by your team. Report ulcers, white patches or soreness that limits eating, because infection or dehydration may need treatment. Avoid very hot, acidic or spicy foods if they sting. Moisturise dry skin with a simple fragrance-free product and protect it from strong sunlight. Painful skin, blisters or rapidly worsening redness need medical assessment rather than a new cosmetic product.

Important side effects

Severe skin reactions

Rare reactions can cause widespread blistering and peeling of skin or injury to the lining of the mouth and other surfaces. They can be life-threatening and may occur in the first cycle. Painful spreading redness, blisters, peeling, mouth sores or fever with rash needs immediate medical assessment. Suspected Stevens–Johnson syndrome or toxic epidermal necrolysis requires immediate withholding and specialist assessment. Confirmed cases, very severe skin reactions or recurrent severe skin reactions require permanent discontinuation.

Very high blood sugar and ketoacidosis

Excessive thirst, frequent urination, increasing fatigue or blurred vision may signal high glucose. Vomiting, abdominal pain, deep or rapid breathing, fruity-smelling breath, confusion or marked drowsiness may indicate ketoacidosis, an emergency. It can happen without previously diagnosed diabetes.

Lung inflammation

New cough, breathlessness or fever can reflect pneumonitis or infection. Risk and assessment differ when pembrolizumab is also used. Report symptoms promptly; severe breathing difficulty requires emergency care. Do not decide at home which of the two medicines is responsible. Moderate pneumonitis requires a treatment pause; severe pneumonitis requires permanent discontinuation, as assessed by the specialist.

Severe infection or an allergic reaction

A serious infection can occur even without a high temperature, especially if steroids or fever-reducing medicines are being taken. New confusion, marked drowsiness, rapid breathing or collapse requires emergency care. Sudden throat swelling, severe wheezing or faintness can indicate a severe allergic reaction. These symptoms should not be managed by waiting at home for the next scheduled review.

Other medicines and vaccinations

Medicines that strongly inhibit both CYP3A4 and P-glycoprotein may increase exposure to the attached drug. The pharmacist should check antifungals, antibiotics, antiviral medicines and all other products. Steroids and other medicines can alter glucose; never stop essential prescribed steroids yourself. Pembrolizumab adds separate immune-related precautions and may require urgent assessment of symptoms that are not typical ADC effects.

Ask the oncology pharmacist to check new prescriptions, over-the-counter remedies and herbal or traditional products. Products described as natural are not necessarily safe with cancer treatment. Do not use an unproven supplement in place of an essential supportive medicine. Keep the team informed about medicines prescribed by other specialists so that advice is coordinated.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines may be suitable, although the response can be reduced during treatment. Live vaccines require specific specialist advice. Timing after treatment depends on immune recovery and the complete regimen; there is no single waiting interval that is correct for every ADC-treated patient.

Everyday life

Eating does not determine absorption of this intravenous medicine. Aim for enough food and fluids, adjusting for nausea and following any kidney, heart or diabetes restrictions. Avoid a restrictive anticancer diet that causes weight loss. Discuss alcohol with the team, particularly if liver tests are abnormal or other medicines cause sedation.

Work may remain possible with flexible hours and time for appointments. Increase activity gradually and avoid tasks that become unsafe because of fatigue, poor balance or impaired vision. Do not drive if dizzy, sleepy, visually affected or unable to use the pedals safely. Sedating premedicines can also affect driving, so arrange transport for early appointments until you know the plan.

Inspect your skin and feet regularly. Use comfortable footwear if sensation is reduced and take care with hot surfaces. If glucose monitoring was prescribed, carry the equipment and agreed action plan. Do not use a normal reading as reassurance when you are acutely unwell or have breathing or neurological symptoms.

Discuss travel before booking, especially long journeys or travel far from urgent care. Carry your treatment summary and enough supportive medicines. Use careful hand hygiene and food safety; avoid close contact with people who are clearly infectious. Complete social isolation is not automatically required. Ask about additional precautions when blood counts are very low.

Sex is often possible if comfortable, with the pregnancy precautions below and any advice about infection or bleeding. Ask the team whether barrier protection is needed after a dose to reduce exposure to drug residues in body fluids; the interval depends on the treatment. Caregivers cleaning urine, stool or vomit should follow the unit's handling advice, wear gloves when instructed and wash their hands afterwards. Keep medicines away from children and pets.

Fertility, pregnancy and breastfeeding

Use effective contraception during treatment. US information specifies two months after the final dose for a treated person who can become pregnant and four months for a treated man with a partner who could become pregnant. EU information specifies at least six months for women and four months for men. Do not breastfeed during treatment: US instructions specify three weeks afterwards, while EU instructions specify at least six months. Agree a clear plan with your team for the exact product and accompanying pembrolizumab; do not select the shortest interval yourself.

Pregnancy should be discussed before treatment and reported promptly if it occurs or is suspected. Loss of periods does not reliably mean pregnancy is impossible. Vomiting or severe diarrhoea can interfere with oral contraception; seek advice about additional protection if this happens. Accompanying medicines may require longer precautions than the ADC itself, so obtain one clear end date for the complete regimen.

Fertility may be affected by treatment and previous therapies, and recovery cannot be guaranteed. Discuss sperm, egg or embryo preservation before starting when feasible. The interval for avoiding pregnancy is a safety precaution and does not itself establish whether fertility has recovered.

After treatment

Skin injury and nerve symptoms may need continuing care after the final dose. If pembrolizumab was part of treatment, immune complications can also appear after dosing ends. Keep both medicines in your treatment history and report new breathing, skin or neurological symptoms promptly.

Keep attending the recommended blood tests, scans and clinical reviews. Retain a treatment summary with the exact ADC name, dates, significant reactions and any ongoing medication. Tell new clinicians about past treatment when an unexplained symptom is assessed. Continue contraception, breastfeeding restrictions and prescribed supportive medicines for their own specified periods, counted from the relevant final dose.

Recovery can be gradual and may involve physical rehabilitation, dietary support or help with anxiety and sleep. A follow-up visit is also an opportunity to discuss returning to work, travel and persistent symptoms. New severe symptoms still need urgent assessment between appointments; finishing treatment does not remove the need for the urgent-care plan.

Common questions